NASDAQ:BNTXBioNTech Stock Price, Forecast & News

BioNTech's stock was trading at $32.17 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, BNTX shares have increased by 115.5% and is now trading at $69.34. View which stocks have been most impacted by Coronavirus.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioNTech in the last year. There are currently 5 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for BioNTech.

BioNTech SE (NASDAQ:BNTX) posted its earnings results on Tuesday, May, 12th. The company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.04. The business had revenue of $30.51 million for the quarter, compared to analyst estimates of $27.90 million. View BioNTech's earnings history.

8 brokerages have issued 12 month price objectives for BioNTech's stock. Their forecasts range from $21.00 to $63.00. On average, they anticipate BioNTech's share price to reach $43.56 in the next year. This suggests that the stock has a possible downside of 37.2%. View analysts' price targets for BioNTech.

News articles about BNTX stock have trended negative recently, according to InfoTrie Sentiment. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. BioNTech earned a news impact score of -2.1 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news about BioNTech.

Some companies that are related to BioNTech include Biogen (BIIB), Seattle Genetics (SGEN), Moderna (MRNA), NOVOZYMES A/S/S (NVZMY), Neurocrine Biosciences (NBIX), argenx (ARGX), BIO-TECHNE (TECH), Qiagen (QGEN), Repligen (RGEN), Adaptive Biotechnologies (ADPT), Allogene Therapeutics (ALLO), Acceleron Pharma (XLRN), Crispr Therapeutics (CRSP), Novavax (NVAX) and Spark Therapeutics (ONCE). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other BioNTech investors own include Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Moderna (MRNA), Advanced Micro Devices (AMD), Micron Technology (MU), Johnson & Johnson (JNJ), Pfizer (PFE), Regeneron Pharmaceuticals (REGN), Walt Disney (DIS) and NVIDIA (NVDA).

(BNTX) raised $251 million in an initial public offering on Thursday, October 10th 2019. The company issued 13,200,000 shares at $18.00-$20.00 per share. J.P. Morgan, BofA Merrill Lynch, UBS Investment Bank and SVB Leerink acted as the underwriters for the IPO and Canaccord Genuity, Bryan, Garnier, Berenberg, Wolfe Capital Markets and Advisory, Kempen and Mirae Asset Securities were co-managers.

BioNTech trades on the NASDAQ under the ticker symbol "BNTX."

Shares of BNTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of BNTX stock can currently be purchased for approximately $69.34.

BioNTech has a market capitalization of $15.69 billion and generates $121.63 million in revenue each year. The company earns $-200,540,000.00 in net income (profit) each year or ($0.95) on an earnings per share basis. BioNTech employs 1,310 workers across the globe.

The official website for BioNTech is www.biontech.de.

BioNTech's mailing address is AN DER GOLDGRUBE 12, MAINZ 2M, 55131. The company can be reached via phone at 49-61-31908-40 or via email at [email protected]